What is Immunome?
Immunome operates as a specialized biopharmaceutical entity focused on the discovery and development of first-in-class antibody therapeutics. By leveraging a proprietary human memory B cell platform, the company identifies novel therapeutic targets directly from the immune systems of patients who have successfully combated specific diseases. This innovative discovery engine is primarily directed toward oncology and infectious disease treatment, including high-impact research into COVID-19. By utilizing the highly educated components of the human immune response, Immunome aims to redefine standard treatment protocols and improve patient outcomes through precision medicine and targeted biological interventions.
How much funding has Immunome raised?
Immunome has raised a total of $201.4M across 8 funding rounds:
Debt
$846K
Debt
$892K
Private Equity
$3.6M
Series A
$5M
Debt
$350K
Stock Offering
$39M
Share Placement
$27M
Share Placement
$124.7M
Debt (2010): $846K, investors not publicly disclosed
Debt (2014): $892K, investors not publicly disclosed
Private Equity (2015): $3.6M, investors not publicly disclosed
Series A (2016): $5M, investors not publicly disclosed
Debt (2020): $350K backed by PPP
Stock Issuance/Offering (2020): $39M, investors not publicly disclosed
Share Placement (2021): $27M, investors not publicly disclosed
Share Placement (2023): $124.7M, investors not publicly disclosed
Key Investors in Immunome
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Immunome?
Following this major enterprise-level funding, Immunome is positioned to scale its operational infrastructure and advance its lead candidates through critical clinical trial phases. The strategic allocation of this capital will likely prioritize the expansion of its proprietary discovery platform, enabling the firm to explore new therapeutic modalities and broaden its oncology portfolio. As the company transitions into a more mature phase of development, the focus will shift toward regulatory milestones and potential commercialization partnerships. Investors and industry stakeholders will be monitoring the firm's ability to translate its unique B cell insights into scalable, market-ready therapeutics that address significant unmet medical needs in the global healthcare market.
See full Immunome company page
